We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Serotonin/Dopamine Antagonism of Cocaine Effect: 2 - 2

This study has been terminated.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00000310
First Posted: September 21, 1999
Last Update Posted: January 16, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
VA Boston Healthcare System
Information provided by:
National Institute on Drug Abuse (NIDA)
  Purpose
The purpose of this study is to evaluate use of risperidone with cocaine abusers. Study measures incorporate an appropriate integration of behavioral and neurobiological indices.

Condition Intervention Phase
Cocaine-Related Disorders Drug: Risperidone Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: Double
Primary Purpose: Treatment
Official Title: Serotonin/Dopamine Antagonism of Cocaine Effect

Resource links provided by NLM:


Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Urine toxicology for cocaine
  • Analog mood scales
  • POMS
  • EPS sx

Estimated Enrollment: 0
Study Start Date: January 1996
Study Completion Date: March 1996
Primary Completion Date: March 1996 (Final data collection date for primary outcome measure)
Detailed Description:
Risperidone in low doses is compared with placebo in a 6-week randomized trial. Subjects also receive supportive counseling. Outcome measure include rating of behavior, mood, drug abuse, global function, and urine toxicology.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Cocaine abuse or dependence

Exclusion Criteria:

Dependence on other drugs. Major psychiatric illness

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000310


Locations
United States, Rhode Island
Brown University School of Medicine
Providence, Rhode Island, United States, 2906
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
VA Boston Healthcare System
Investigators
Principal Investigator: Lawrence Price, M.D. Brown University
  More Information

ClinicalTrials.gov Identifier: NCT00000310     History of Changes
Other Study ID Numbers: NIDA-09330-2
R01-09330-2
First Submitted: September 20, 1999
First Posted: September 21, 1999
Last Update Posted: January 16, 2017
Last Verified: January 1996

Keywords provided by National Institute on Drug Abuse (NIDA):
cocaine dependence

Additional relevant MeSH terms:
Cocaine-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Risperidone
Cocaine
Dopamine
Serotonin
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Dopamine Antagonists
Dopamine Agents
Anesthetics, Local
Anesthetics
Sensory System Agents
Peripheral Nervous System Agents
Vasoconstrictor Agents
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Cardiotonic Agents
Sympathomimetics
Autonomic Agents